Y. Bhurgri ( Karachi Cancer Registry1, Department of Pathology,Khan University Hospital2, Department of Pathology, Sindh Medical College3, )
A. Mazhar ( Karachi Cancer Registry1, )
H. Bhurgri ( Karachi Cancer Registry1, Department of Pathology,Khan University Hospital2, )
A. Usman ( Jinnah Postgraduate Medical Centre4 )
J. Malik ( Ziauddin Cancer Hospital5, Karachi. )
A. Bhurgri ( Karachi Cancer Registry1,Department of Pathology, Sindh Medical College3 )
R.Ahmed ( Department of Pathology,Khan University Hospital2 )
S. Muzaffar 2 ( Department of Pathology,Khan University Hospital2 )
N. Kayani ( Department of Pathology,Khan University Hospital2 )
S. Pervez ( Department of Pathology,Khan University Hospital2 )
S. H. Hasan 2 ( Department of Pathology,Khan University Hospital2 )
Objective: To study the epidemiology of ocular Rhabdomyosarcoma (ORMS) in Karachi.
Methods: Incident ORMS cases resident of Karachi, registered at Karachi Cancer Registry (KCR) during 1st January 1998 to 31st December 2002 were included in the study. The data were classified using ICD-O2; computerized with Canreg-3, and analyzed using SPSS 10.0.
Results:Ten cases of ORMS were reported to KCR during 1998-2002. RMS originated in the orbit in eight cases, conjunctiva in one and eyelid in one. Nine cases presented with proptosis, associated with conjunctivitis in four cases. One case presented with eyelid swelling. The crude annual incidence rate was 0.13/100,000, the age standardized rate was 0.3/100,000. The mean age of childhood cases was 10.4 years (95% CI 4.0; 16.7); and adult cases was 24.8 years (95% CI 12.8; 36.7). At presentation, eight patients were older than 10 years and three were older than 20 years. Five cases were categorized as childhood malignancies. Tumors were a TNM stage III disease at presentation in eight cases; survival at the end of one year was 70%, and at the end of two years 20%. There were no survivors at the end of three years.
Conclusion: ORMS in Karachi is a disease with a dismal survival. It may reflect a late presentation, or shorter adult ORMS survival or a manifestation of a different genetic pattern, associated with rapid evolution and poor prognosis. Health education for the population, especially parents and health providers is essential for early ORMS diagnosis. Pediatricians, ophthalmologists and health professionals, can play a vital role. Healthcare planning should focus on capacity building for ophthalmologic screening. Cytogenetic studies are advised to determine the genetic pattern (JPMA 54:561;2004).
Rhabdomyosarcoma (RMS) is composed of cells with histopathological features of striated muscle in various stages of embryogenesis. Ocular RMS (ORMS) is the occurrence of this tumor in the area of the eye, mostly ocular soft tissues but rarely the orbit or ocular adnexal structures and even within the eye. RMS is the most common primary malignancy of the orbit in children; the most common intraocular malignant lesion being retinoblastoma. Primarily a childhood tumor, the average age at presentation is 4-7 years.1-3 RMS has also been observed in adults. 4-9
Derived from primitive undifferentiated mesenchymal cells, RMS can be divided into 4 major histologic categories: embryonal, alveolar, botryoid embryonal, and pleomorphic. Embryonal RMS (ERMS) is the most common subtype observed in children, accounting for 40-60% of all RMS cases in this age group.10,11 These tumors are most commonly observed either in the genitourinary region or the head and neck region.
Histologically, they have high cytologic variability, representing several stages of skeletal muscle morphogenesis. Desmin and muscle specific actin are immunochemical stains used for identifying RMS, though these stain smooth muscle as well. Myogenin and MyoD1 are more specific for skeletal muscle.11 Ultrastructural studies are largely of academic interests and for confirmation of RMS if facilities are available. At present three methods of RMS staging or its modifications are in use, group staging, TNM and Risk classification. (Tables 1-2).12-14 Embryonal RMS (ERMS) cells show a loss of specific genome material from the short arm of chromosome 11 (11p15), suggesting the presence of a tumor suppressor gene. Another molecular feature characteristic of embryonal RMS is its lack of gene amplification. The cellular DNA content of embryonal RMS is hyperdiploid. 15-18
RMS clinically presents with ptosis (droopy eyelid), and/or unilateral proptosis (eye prominence), as a sub-conjunctival tumor, dislocation of the lens, or impairment of ocular mobility. It is usually found in the superonasal orbit (that is under the upper lid near the nose). Due to its variable manifestations it may imitate orbitocellulitis, chalazae, epibulbar papilloma or as naso lacrimal duct obstruction. 11,19,20 Rapid evolution, tumour burden (tumour size >5.cms.) and regional lymph node involvement are indicators of poor prognosis. Computed axial tomography (CT-scan) and magnetic resonance imaging (MRI) typically show a mass adjacent to or attached to one of the ocular or orbital muscles. CT is particularly helpful because it shows orbital bone tumor invasion and characteristic focal calcification. Magnetic resonance (MR) imaging allows this tumor to be differentiated from pseudogliomas, such as Coats disease and retrolental fibroplasia. CT and MR imaging help in the differentiation from dermoid, cavernous hemangioma, and lymphangioma. 21
Early diagnosis, complete surgical resection followed by a combination of chemotherapy and irradiation offer approximately 70 to 90% 3-year survival. RMS is considered controlled if there is no recurrence after 3 years. 22,24 The objective was to study the epidemiology of ORMS and identify it as a malignancy with a good prognosis if diagnosed and treated early.
Incident RMS cases recorded at the Karachi Cancer Registry during 1st January 1998 to 31st December 2002 were reviewed. The data were classified using ICD-O2 (International Classification of Diseases-Oncology, 2nd edition) and computerized using a customized version of Canreg-3, with internal checks on the validity of the entered data. 19 Manual and computerized validity checks for the
|Table 1. ORMS staging system. |
|Group staging system || || || |
|Group I ||13% ||localized disease ||complete surgical resection ||no regional nodal involvement. |
|Group IIA ||21% ||Grossly resected ||microscopic residual disease ||no regional involvement. |
| || ||complete resection ||no residual disease ||regional nodal involvement. |
|Group IIC || || ||microscopic residual disease ||regional nodal involvement. |
|Group III ||48% ||incomplete resection ||gross residual disease. || |
|Group IV ||18% ||Distant metastasis || || |
| || || |
|TNM staging system || |
|Stage I ||Disease is localized and involves the orbit, the || |
| ||head and neck region || |
|Stage II ||Localized disease of any unfavorable primary ||The primary tumor must be < or = 5 cm in |
| ||site not included in the stage I category. ||diameter. |
|Stage III ||Localized disease of any unfavorable ||Primary tumor is > 5 cm in diameter and/or |
| ||primary site not included in the ||it involves regional lymph nodes. |
|Stage IV ||Metastatic disease at the time of diagnosis. || |
| || || |
|Risk classification || |
|Low risk ||(1) occurring at a favorable site (stage I) || |
|(Embryonal RMS) ||(2) occurring at an unfavorable site with complete resection (group I), |
| ||(3) occurring at an unfavorable site with microscopic residual disease (group II) |
|Intermediate risk ||(1) embryonal RMS occurring at an unfavorable site with gross residual |
| ||disease (group III) |
| ||(2) metastatic embryonal RMS and are younger than 10 years |
| ||(3) any nonmetastatic alveolar RMS at any site |
|High risk ||Metastatic disease unless younger than 10 years and have embryonal metastasis |
| || || |
cancer data were performed as per recommendations of International Agency for Research on Cancer (IARC) and International Association of Cancer Registries (IACR).25-27 This involved factors influencing comparability i.e., classification and coding. For precision only cases diagnosed microscopically were included in the study. The residency status of cases was re-ascertained and rechecked. People residing in the specified geographical regions for more than six months were considered residents. Demographical variables recorded were the hospital patient-number, date of incidence, name, age, sex, address, ethnicity, topography, morphology, grading and staging. Tumors were categorized according to the UICC, TNM staging system, to standardize with the staging systems in other parts of the world. 12
Incidence rates were calculated based on the 1998 census (copy obtained from the Sindh Bureau of Statistics), assuming an annual growth rate of 3.5%. 28 The growth rate was based on the inter-census growth-rate and measures for inflow and outflow of population, calculated by the Federal Bureau of Statistics. Standardized incidence rate was
|Table 2. ORMS comparative studies. |
| ||Feng et al3 ||Takahashi et al2 ||Haik et al30 ||Shields et al22 ||Karachi |
| ||(n=10) ||(n=35) ||(n=18) ||(n=33) ||(n=10) |
|Orbit ||9 ||- ||4 ||25 ||8 |
|Conjunctiva ||1 ||- ||14 ||4 ||1 |
|Eyelid ||2 ||- || ||1 ||1 |
|Uveal tract ||- ||- || ||3 || |
| || || || || || |
|Proptosis ||- ||- ||- ||10 ||5 |
|Eyelid ||- ||- ||- ||7 ||1 |
|Blepharoptosis ||- ||- ||- ||6 ||4 |
| || || || || || |
|Initial diagnoses || || || || || |
|Rhabdomyosarcoma ||- ||- ||- ||8 ||10 |
|Conjunctivitis ||- ||- ||- ||5 ||- |
|Cellulitis ||- ||- ||- ||5 ||- |
|Pseudotumor ||- ||- ||- ||4 ||- |
| || || || || || |
|Mean age ||4.2 ||5.2 ||6.0; 21.0 ||10.0 ||10.4; 24.8 |
|Recurrence (total) ||- ||43 ||15 ||10 ||2 |
|Local ||- ||- ||- ||6 ||2 |
|Lymph node spread ||- ||20 ||8 ||2 ||- |
|Distant metastasis ||- ||23 ||7 ||2 ||- |
|Tumor-related death ||- ||- ||7 ||1 ||10 |
calculated with an external reference population, the 'world' population with a given 'standard' age distribution. 29 The methodology applied was direct standardization, using 5-year age groups. The rates given are the annual incidence per 100,000 population, averaged over the number of years for which data are presented. The data were analyzed using SPSS 10.0.
Eighteen cases of RMS were reported to the Karachi Cancer Registry during a five-year period, 1998-2002. Ten cases were residents of Karachi Division (population of 9,802,134; males 5,261,712, females 4,540,422). RMS originated in the orbit in eight (80%) cases, conjunctiva in one (10%) case and eyelid in one (10%) case. Nine cases presented with proptosis, associated with conjunctivitis in four cases. One case presented with eyelid swelling. Six cases were observed in the right eye, whereas four were observed in the left eye. The crude annual incidence rate was 0.13/100,000, the age standardized rate was 0.3/100,000.
The mean age of childhood cases was 10.4 years (95% CI 4.0; 16.7); minimum 3 years, maximum 14 years, range, 11 years. The mean age of adult cases was 24.8 years (95% CI 12.8; 36.7); minimum 16 years, maximum 35 years, range, 19 years. At presentation, eight patients (80%) were older than age 10 years and three patients (30%) were older than 20 years. Only five cases (50%) could be categorized as childhood malignancies (0-14 years). Two cases presented at the age of 35 years, a male and a female. The gender ratio (M:F) was 2.3.
All ten cases were clinically diagnosed as RMS, and histologically verified. Immunochemistry studies were positive for desmin, vimentin, and HHf35 actin and negative for epithelial markers, (Cytokeratin CAM 5.2 and MNF) and S100. Leucocyte Common Antigen (LCA), PAN B and T, and retinoblastoma markers were also negative. Ultra structural and cytogenetic studies were not conducted on any histopathological specimen. Treatment included multimodality effort, which included surgical debulking and/or enucleation, chemotherapy, and radiotherapy for all patients. Tumors classified according TNM staging were a stage III disease at presentation in eight (80%) cases and stage I in two (20%) cases. The two Stage I, RMS were adult cases, both presented with a
recurrence within a year of treatment. Survival at the end of one year was 70% and at the end of two years 20%. There were no survivors at the end of 3 years.
ORMS is an uncommon disease, the incidence rates are not calculated, and therefore not a parameter of comparison. There are few published articles, mostly single centre studies, and a few registry reports consisting of 10-35 cases or single case reports of adult ERMS.1-11 Predominantly a childhood malignancy, it is rarely observed in adults. Contrary to this in our series of ten cases, we observed an equal distribution of adult and childhood orbital ERMS.
Most studies report an early presentation and diagnosis, a mass or area of localized swelling usually marks initial presentation. The mean age reported in different series is 5.2 years by Takahashi et al2, 4.2 years by Feng et al3, 6 years by Haik et al30, 7-8 years by Parham11 and 10 years by Sheild et al.22 Amongst children, a late presentation of ORMS was observed in Karachi, despite obvious lesions associated with pain, in half the patients. The mean age at diagnosis was 10.4 years, with two cases presenting at 14 years of age. The mean age being reported, here is therefore the highest documented and the plausible reason could be a late diagnosis. Three out of the five childhood cases presented with an erosion into the paranasal sinuses and facial bones.
Primary ERMS is extremely rare in adults. The oldest documented age is 38 years; the highest age in our series is 35 years. In the adult cases, presentation was earlier, with a time lapse of 3-4 weeks before diagnosis. The presenting complaints were conjunctivitis in four cases, and eyelid swelling in one case.
The cases were categorized by TNM (tumor, node, metastasis) system which takes the size and location into consideration. The other available options were 'Initial staging system', adopted by the first 3 intergroup RMS studies, which group patients based on extent of disease and completeness of initial surgical resection. As we did not have reliable information of the surgical process and residual disease this system could not be utilized. The TNM staging does not take the extent of surgery into account, thus it was more feasible for our system. The risk classifications, is more appropriate for planning treatment options.
The survival in Karachi is the lowest reported in literature. Shield et al22 reported a 70% 5-year survival with gross disease following surgery (Risk group III); 90% 5-year survival in patients without residual disease (Risk group I) and an 80% 5-year survival with microscopic residual disease (Risk group II), when ORMS is seen in children younger than 10 years of age. Takahashi2 et al reported a 52% 3-year survival in 1970's, and 86% in the 1980's in childhood ORMS. Haik30 et al reported a 61% six-year survival.
Cytogenetic studies were not conducted therefore one remains in doubt if the late mean age of childhood ORMS and the adult presentation are not a manifestation of a different genetic pattern, more compatible with a rapid evolution and poor prognosis.
ORMS in Karachi is a disease with a poor prognosis and a dismal survival. Cytogenetic studies are advised to determine the genetic pattern. Health education for the population, especially parents and health providers is essential for early ORMS diagnosis. Pediatricians, ophthalmologists and health professionals, can, play a vital role. Healthcare planning should focus on capacity building for ophthalmologic screening.
1. Gunalp I, Duruk K, Gunduz K. Orbital rhabdomyosarcoma: a twenty-year survey in Turkey. Jpn J Ophthalmol 1993;37:499-504.
2. Takahashi N, Minoda K. Prognosis of orbital rhabdomyosarcoma in children in Japan. Jpn J Ophthalmol 1991;35:292-9.
3. Feng G, Yi Y, Zhang J, et al. Clinicopathological analysis of rhabdomyosarcoma of the ocular adenexa. Yan Ke Xue Bao 1994;10:125-8.
4. Mamalis N, Grey AM, Good JS, et al. Embryonal rhabdomyosarcoma of the orbit in a 35-year-old man.Ophthalmic Surg 1994;25:332-5.
5. Cernea P, Simionescu C, Glavici A. Embryonal rhabdomyosarcoma of the orbit, Ophthalmologia 1994;38:118-24.
6. Cameron JD, Wick MR. Embryonal rhabdomyosarcoma of the conjunctiva: a clinicopathologic and immunohistochemical study. Arch Ophthalmol 1986;104:1203-4.
7. Hardaway CA, Graham BS, Barnette DJ, et al. Embryonal rhabdomyosarcoma presenting in an adult: a case report and discussion of immunohistochemical staining. Am J Dermatopathol 2003;25:45-52.
8. Mulugeta A, Bejiga A, Bezabih K. Embryonal rhabdomyosarcoma of the orbit in a 38-year-old woman. Ethiop Med J 2001;39:47-51.
9. Marucci G, Galliani E, Marrocolo F, et al. Orbital embryonal rhabdomyosarcoma in adults. Report of 2 cases. Pathologica 1999;91:459-65.
10. Offret G, Dhermy P, Offret H, et al. Embryonal rhabdomyosarcoma of the orbit. Apropos of 24 cases. Arch Ophthalmol (Paris) 1976;36:709-32.
11. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001;14:506-14.
12. Lawrence W Jr, Anderson JR, Gehan EA. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Children's Cancer Study Group. Pediatric Oncology Group. Cancer 1997;80:1165-70.
13. Maurer HM, Beltangady M, Gehan EA. The Intergroup Rhabdomyosarcoma Study-I:.a final report. Cancer 1988;61:209-20.
14. Maurer HM, Gehan EA, Beltangady M. The Intergroup Rhabdomyosarcoma Study-II. Cancer 1993;71:1904-22.
15. Merlino G, Helman LJ. Rhabdomyosarcoma - working out the pathways. Oncogene 1999;18:5340-8.
16. Koufos A, Hansen MF, Copeland NG, et al. Loss of heterozygosity in three embryonal tumours suggests a common pathogenetic mechanism. Nature 1985;316:330-4.
17. Scrable H, Witte D, Shimada H, et al. Molecular differential pathology of rhabdomyosarcoma. Genes Chromosomes. Cancer 1989;1:23-35.
18. Gordon T, McManus A, Anderson J, et al. United kingdom Children's Cancer Study Group: United Kingdom Cancer Cytogenetics Group: Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom. Cancer Cytogenetics Group Study. Med Pediatr Oncol 2001;36:259-67.
19. Baron EM, Kersten RC, Kulwin DR. Rhabdomyosarcoma manifesting as acquired nasolacrimal duct obstruction. Am J Ophthalmol 1993;115:239-42.
20. Gerinec A, Chynoransky M, Galbavy S. Rhabdomyosarcoma of the orbit, Cesk Slov Ofthamol 1997;53:11-17.
21. Hopper KD, Sherman JL, Boal DK, et al. CT and MR imaging of the pediatric orbit. Radiographics 1992;12:485-503.
22. Shields JA, Shields CL. Rhabdomyosarcoma: review for the ophthalmologist. Surv Ophthalmol 2003;48:39-57.
23. Fiorillo A, Migliorati R, Grimaldi M, et al. Multidisciplinary treatment of primary orbital rhabdomyosarcoma: a single-institution experience. Cancer 1991;67:560-3.
24. Morgan KS, Braverman DE, Baker JD. The correction of unilateral aphakia in children treated for orbital rhabdomyosarcoma. J Pediatr Ophthalmol Strabismus 1990;27:70-2.
25. World Health Organization. International Classification of Diseases for Oncology, 2nd ed. Geneva: WHO, 1990.
26. Parkin DM, Chen VW, Ferley J (eds.) Comparability and quality control in cancer registration. IARC Technical Report No. 19. International Agency for Research on Cancer Lyon, 1994.
27. Skeet RC. Quality and Quality Control. In: Jenson OM, Parkin DM, McLennam R (eds.) Cancer registration: principles and methods, IARC Scientific Publications No. 95. International Agency for Research on Cancer Lyon, 1991.
28. Federal Bureau of Statistics. Population Census Organization. Statistics division, Population and Housing Census of Pakistan, Islamabad: FBS, 1998.
29. Segi M. Cancer mortality in selected sites in 24 Countries (1950-57), Sendai: Tohoku University School of Public Health, 1960.
30. Haik BG, Jereb B, Smith ME, et al.Radiation and chemotherapy of parameningeal rhabdomyosarcoma involving the orbit. Ophthalmology 1986;93:1001-9.